Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 3;16(11):100837.
doi: 10.1016/j.waojou.2023.100837. eCollection 2023 Nov.

Unanswered questions on the use of biologics in pediatric asthma

Antonio Nieto  1 , Zeinab A El-Sayed  2 , René Maximiliano Gómez  3 , Elham Hossny  2 , Wang Jiu-Yao  4 , Ömer Kalayci  5 , Mário Morais-Almeida  6 , Wanda Phipatanakul  7 , Paulo Marcio Pitrez  8 , César Fireth Pozo Beltrán  9 , Paraskevi Xepapadaki  10 , Nikolaos G Papadopoulos  10   11
Affiliations
Review

Unanswered questions on the use of biologics in pediatric asthma

Antonio Nieto et al. World Allergy Organ J. .

Abstract

The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease. Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can be expected in the coming years. This will facilitate the transition to the paradigm of personalized medicine, but on the other hand will decisively further complicate the choice of the most appropriate treatment, in the absence of reliable enough biological markers. For these reasons, along with the relatively short time of use with these treatments, there are recurrently arising questions for which there are not even moderately documented answers, and for which the only solution must be based, with all reservations, on the combination of indirect evidence and expertise. In this paper, we attempt to address such questions, providing relevant commentaries and considering the whole width of the evidence base.

Keywords: Benralizumab; Biologics; Dupilumab; Mepolizumab; Omalizumab; Severe childhood asthma; Tezepelumab.

PubMed Disclaimer

Conflict of interest statement

None to declare related to this work.

References

    1. Santos-Valente E., Buntrock-Döpke H., Abou Taam R., et al. Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo. ERJ Open Res. 2021;7(3):00143–02021. - PMC - PubMed
    1. Just J., Deschildre A., Lejeune S., Amat F. New perspectives of childhood asthma treatment with biologics. Pediatr Allergy Immunol. 2019 Mar;30(2):159–171. - PubMed
    1. Deschildre A., Marguet C., Langlois C., et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015 Sep;46(3):856–859. - PubMed
    1. Nieto García A., Garriga-Baraut T., Plaza Martín A.M., et al. Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma. Pediatr allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2021 Feb;32(5):980–991. - PubMed
    1. Licari A., Castagnoli R., Denicolò C., et al. Omalizumab in children with severe allergic asthma: the Italian real- life experience. Curr Respir Med Rev. 2017;13:36–42. - PMC - PubMed

LinkOut - more resources